| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Machatha Stephen | Chief Development Officer | C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, LEXINGTON | /s/ Stephen Machatha | 13 Aug 2025 | 0001836354 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ALDX | Common Stock | Sale | $113,713 | -22,073 | -9.1% | $5.15 | 221,799 | 11 Aug 2025 | Direct | F1, F2, F3 |
| Id | Content |
|---|---|
| F1 | These shares of common stock were sold in a transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards. |
| F2 | Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $5.06 to $5.29. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. |
| F3 | Includes 7,101 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan. |